ATE277014T1 - Verfahren zur herstellung des mesylat-trihydrat- salzes von 1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol - Google Patents

Verfahren zur herstellung des mesylat-trihydrat- salzes von 1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol

Info

Publication number
ATE277014T1
ATE277014T1 AT01303705T AT01303705T ATE277014T1 AT E277014 T1 ATE277014 T1 AT E277014T1 AT 01303705 T AT01303705 T AT 01303705T AT 01303705 T AT01303705 T AT 01303705T AT E277014 T1 ATE277014 T1 AT E277014T1
Authority
AT
Austria
Prior art keywords
phenylpiperidin
hydroxyphenyl
propanol
hydroxy
producing
Prior art date
Application number
AT01303705T
Other languages
English (en)
Inventor
Joseph Philip Rainville
Terry Gene Sinay Jr
Stanley Walter Walinsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE277014T1 publication Critical patent/ATE277014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
AT01303705T 2000-04-28 2001-04-24 Verfahren zur herstellung des mesylat-trihydrat- salzes von 1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol ATE277014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
ATE277014T1 true ATE277014T1 (de) 2004-10-15

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01303705T ATE277014T1 (de) 2000-04-28 2001-04-24 Verfahren zur herstellung des mesylat-trihydrat- salzes von 1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol

Country Status (27)

Country Link
US (1) US6645986B2 (de)
EP (2) EP1477479A1 (de)
JP (2) JP3615496B2 (de)
KR (1) KR100442718B1 (de)
CN (2) CN1210262C (de)
AR (1) AR028376A1 (de)
AT (1) ATE277014T1 (de)
AU (1) AU781436B2 (de)
BR (1) BR0101630A (de)
CA (1) CA2345582C (de)
CZ (1) CZ20011471A3 (de)
DE (1) DE60105689T2 (de)
DK (1) DK1151995T3 (de)
ES (1) ES2227071T3 (de)
HK (1) HK1040246B (de)
HU (1) HUP0101723A3 (de)
ID (1) ID30006A (de)
IL (1) IL142705A0 (de)
IN (1) IN191027B (de)
PL (1) PL347298A1 (de)
PT (1) PT1151995E (de)
RU (1) RU2203888C2 (de)
SI (1) SI1151995T1 (de)
TR (1) TR200402696T4 (de)
TW (1) TW200505858A (de)
YU (1) YU27701A (de)
ZA (1) ZA200103320B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE319087T1 (de) * 2000-06-21 2006-03-15 Bioarray Solutions Ltd Multianalytische molekularanalyse durch verwendung anwendungsspezifischer zufallspartikelarrays
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CA2545653C (en) 2003-11-21 2014-07-08 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
US8563329B2 (en) 2005-05-02 2013-10-22 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
UA59341C2 (uk) * 1995-08-11 2003-09-15 Пфайзер, Інк. (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат

Also Published As

Publication number Publication date
HK1040246B (zh) 2005-10-28
EP1151995B1 (de) 2004-09-22
PL347298A1 (en) 2001-11-05
ES2227071T3 (es) 2005-04-01
ZA200103320B (en) 2002-10-24
SI1151995T1 (en) 2004-12-31
PT1151995E (pt) 2004-11-30
AR028376A1 (es) 2003-05-07
CZ20011471A3 (cs) 2002-02-13
CN1210262C (zh) 2005-07-13
HUP0101723A2 (hu) 2002-02-28
CA2345582A1 (en) 2001-10-28
IL142705A0 (en) 2002-03-10
JP2001354651A (ja) 2001-12-25
DE60105689T2 (de) 2005-11-10
EP1151995A1 (de) 2001-11-07
YU27701A (sh) 2003-04-30
US20020016465A1 (en) 2002-02-07
TW200505858A (en) 2005-02-16
US6645986B2 (en) 2003-11-11
RU2203888C2 (ru) 2003-05-10
TR200402696T4 (tr) 2004-11-22
IN191027B (de) 2003-09-13
CA2345582C (en) 2006-05-30
BR0101630A (pt) 2001-12-04
AU3889601A (en) 2001-11-01
CN1590373A (zh) 2005-03-09
JP2004196823A (ja) 2004-07-15
KR100442718B1 (ko) 2004-08-02
HK1040246A1 (en) 2002-05-31
CN1321638A (zh) 2001-11-14
KR20010098960A (ko) 2001-11-08
DK1151995T3 (da) 2004-12-13
JP3615496B2 (ja) 2005-02-02
AU781436B2 (en) 2005-05-26
EP1477479A1 (de) 2004-11-17
HUP0101723A3 (en) 2003-03-28
DE60105689D1 (de) 2004-10-28
ID30006A (id) 2001-11-01
HU0101723D0 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
ATE291574T1 (de) Neuer prozess zur herstellung von s-omeprazol- magnesiumsalz-trihydrat
ATE258097T1 (de) Verfahren zur herstellung von mikroschleifenden werkzeugen
ATE297892T1 (de) Verfahren zur herstellung von azetidinonen
DE60008136D1 (de) Verbessertes verfahren zur herstellung von n-substituierte aminotetraline
ATE353322T1 (de) Verfahren zur herstellung von 2- (chinoxalin-5- ylsulfonylamino) -benzamid-verbindungen
ATE339484T1 (de) Verfahren zur herstellung von fischer-tropsch- wachsen
DE50002380D1 (de) Verfahren und arbeitsmaschine zur herstellung von bodenflächen
DE69919412D1 (de) Verfahren zur herstellung von polyolefine
ATE249417T1 (de) Verfahren zur herstellung von l- phenylephrinhydrochlorid
DE69908824D1 (de) Verfahren zur herstellung von bisphenol-a
DE69921450D1 (de) Verfahren zur herstellung von behandelter kieselsäure
DE69919408D1 (de) Verfahren zur herstellung von polyolefine
ATE296287T1 (de) Verfahren zur herstellung von repaglinide
ATE364042T1 (de) Verfahren zur herstellung von thiamethoxam
DE50006772D1 (de) Verfahren zur herstellung von oxindolen
ATE234269T1 (de) Verfahren zur herstellung von cis-1-2-(4-(6-
ATE277014T1 (de) Verfahren zur herstellung des mesylat-trihydrat- salzes von 1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol
ATE349442T1 (de) Verbessertes verfahren zur herstellung von alpha- polymorphem eletriptan hydrobromid
DE60030166D1 (de) Verfahren zur herstellung von polycarbonaten
DE60001902D1 (de) Verfahren zur herstellung titankomplexen
DE50001895D1 (de) Verfahren zur herstellung von phosphonomethylglycin
ATE292122T1 (de) Verfahren zur herstellung von den sulfonylaminocarbonyl-triazolinonsalzen
ATE280779T1 (de) Verfahren zur herstellung von lhrh-antagonisten
ATE233238T1 (de) Verfahren zur herstellung von 3-acyl-indolen
DE60014347D1 (de) Verfahren zur herstellung von cyclopropylacetonitril

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1151995

Country of ref document: EP

REN Ceased due to non-payment of the annual fee